Castleman Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CST005 MIFTS: 53	Castleman Disease Categories: Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Castleman Disease

MalaCards integrated aliases for Castleman Disease:

Name: Castleman Disease ¹² ⁵⁴ ³⁸ ⁵⁶ ⁴⁵ ¹⁵

Angiofollicular Ganglionic Hyperplasia ⁵⁴ ⁴⁵ ⁷⁴

Giant Lymph Node Hyperplasia ¹² ⁵⁴ ¹⁷

Angiofollicular Lymph Hyperplasia ¹² ⁵⁴

Castleman's Disease ⁷⁷ ¹⁵

Angiofollicular Lymph Node Hyperplasia ¹²

Angiolymphoid Hyperplasia ⁷⁴

Benign Giant Lymphoma ⁵⁴

Lymphoid Hamartoma ¹²

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0111157

KEGG ³⁸ H01479

MeSH ⁴⁵ C536362 D005871

NCIt ⁵¹ C3056

SNOMED-CT ⁶⁹ 69484003

ICD10 ³⁴ D47.Z2

EFO ¹⁷ EFO_1001332

UMLS ⁷⁴ C0017531 C2931179

Sources

Summaries for Castleman Disease

NIH Rare Diseases : ⁵⁴ Castleman disease (CD) is a rare condition that affects the lymph nodes and related tissues. There are two main forms: unicentric CD and multicentric CD. Unicentric CD is a "localized" condition that is generally confined to a single set of lymph nodes, while multicentric CD is a "systemic" disease that affects multiple sets of lymph nodes and other tissues throughout the body. The exact underlying cause of CD is currently unknown; however, it is thought to occur sporadically in people with no family history of the condition. Treatment varies based on the form of the condition, the severity of symptoms and whether or not the affected person also has an HIV and/or human herpes virus type 8 (HHV-8) infection. For more specific information about each form of CD, please visit GARD's unicentric Castleman disease and multicentric Castleman disease pages.

MalaCards based summary : Castleman Disease, also known as angiofollicular ganglionic hyperplasia, is related to multicentric castleman disease and human herpesvirus 8. An important gene associated with Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Valganciclovir and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include lymph node, b cells and t cells, and related phenotypes are immune system and normal

Disease Ontology : ¹² A lymphoproliferative syndrome characterized by one or more enlarged lymph nodes containing cells with hyaline-vascular, plasmacytic, or mixed appearance microscopically.

Wikipedia : ⁷⁷ Castleman disease is a group of uncommon lymphoproliferative disorders characterized by lymph node... more...

Sources

Related Diseases for Castleman Disease

Diseases related to Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 358)

#	Related Disease	Score	Top Affiliating Genes
1	multicentric castleman disease	33.2	BCL6 CRP IL10 IL6 PAX5
2	human herpesvirus 8	32.6	BCL6 IL6 IL6R
3	primary effusion lymphoma	30.4	BCL6 IL6 VEGFA
4	pemphigus	30.2	DSG1 DSP EVPL PPL
5	paraneoplastic pemphigus	30.1	DSG1 DSP EVPL PPL
6	hodgkin's lymphoma, lymphocytic-histiocytic predominance	30.1	BCL6 CR2
7	pericardial effusion	30.0	CRP IL6 VEGFA
8	bronchiolitis	29.9	CRP IL10 IL6
9	pneumonia	29.9	CRP IL10 IL6
10	follicular dendritic cell sarcoma	29.7	CR1 CR2 DSP EVPL PPL
11	myeloma, multiple	29.7	CRP IL6 IL6R VEGFA
12	appendicitis	29.6	CRP IL10 IL6
13	lymphoma, non-hodgkin, familial	29.6	BCL6 CR2 IL9 PAX5
14	bronchiolitis obliterans	29.5	EVPL IL10 IL6 PPL
15	acute pancreatitis	29.5	CRP IL10 IL6
16	acquired immunodeficiency syndrome	29.4	BCL6 IL10 IL6
17	hemophagocytic lymphohistiocytosis	29.4	CR1 CR2 IL10
18	rheumatoid arthritis	29.3	CRP IL10 IL6 IL6R VEGFA
19	pemphigus vulgaris	29.3	DSG1 DSP EVPL PPL
20	bullous pemphigoid	29.3	DSG1 DSP EVPL PPL
21	human immunodeficiency virus type 1	29.2	CR1 CR2 IL10 IL6
22	systemic lupus erythematosus	28.9	CR1 CR2 CRP IL10 IL6
23	unicentric castleman disease	12.6
24	pediatric castleman disease	12.3
25	kaposi sarcoma	12.0
26	sarcoma	10.6
27	lymphoma	10.5
28	cold agglutinin disease	10.4	CRP IL6
29	glomerulonephritis	10.4
30	membranoproliferative glomerulonephritis	10.4
31	parapharyngeal meningioma	10.4	CR1 CR2
32	poems syndrome	10.4
33	cryopyrin-associated periodic syndrome	10.4	CRP IL6
34	liver inflammatory pseudotumor	10.4	CR2 CRP
35	interdigitating dendritic cell sarcoma	10.3	CR1 CR2
36	acute cholangitis	10.3	CRP IL6
37	congenital heart defects, hamartomas of tongue, and polysyndactyly	10.3
38	viral pneumonia	10.3	CR1 CRP IL6
39	uremic pruritus	10.3	CRP IL6
40	langerhans cell sarcoma	10.3	CR1 CR2
41	preterm premature rupture of the membranes	10.3	CRP IL6 IL6R
42	critical limb ischemia	10.3	IL6 VEGFA
43	t-cell/histiocyte rich large b cell lymphoma	10.2	BCL6 CR1 CR2
44	amyloidosis	10.2
45	tafro syndrome	10.2
46	bullous impetigo	10.2	DSG1 IL6
47	impetigo	10.2	DSG1 IL6
48	neutrophilia, hereditary	10.2	CRP IL6
49	spinal disease	10.2	CRP IL6 VEGFA
50	intermittent claudication	10.2	CRP IL6 VEGFA

Graphical network of the top 20 diseases related to Castleman Disease:

Sources

Symptoms & Phenotypes for Castleman Disease

MGI Mouse Phenotypes related to Castleman Disease:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	9.61	BCL6 CR2 CRP IL10 IL6 IL6R
2	normal	MP:0002873	9.17	BCL6 IL10 IL6R IL9 PAX5 PPL

Sources

Drugs & Therapeutics for Castleman Disease

Drugs for Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Valganciclovir

Approved, Investigational

Phase 4,Phase 2

175865-60-8

64147

Anti-Infective Agents

Phase 4,Phase 2,Phase 1,Early Phase 1

Antiviral Agents

Phase 4,Phase 2,Early Phase 1

Siltuximab

Approved, Investigational

Phase 2,Phase 1,Early Phase 1

541502-14-1

Prednisone

Approved, Vet_approved

Phase 2,Phase 1

53-03-2

5865

Cyclophosphamide

Approved, Investigational

Phase 2,Phase 1

50-18-0, 6055-19-2

2907

Zidovudine

Approved

Phase 2

30516-87-1

35370

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Ganciclovir

Approved, Investigational

Phase 2

82410-32-0

3454

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Vincristine

Approved, Investigational

Phase 2,Phase 1

2068-78-2, 57-22-7

5978

Miconazole

Approved, Investigational, Vet_approved

Phase 2,Phase 1

22916-47-8

4189

Etoposide

Approved

Phase 2,Phase 1

33419-42-0

36462

Doxorubicin

Approved, Investigational

Phase 2,Phase 1

23214-92-8

31703

Sirolimus

Approved, Investigational

Phase 2,Phase 1

53123-88-9

46835353 5284616 6436030

rituximab

Approved

Phase 2,Phase 1

174722-31-7

10201696

Everolimus

Approved

Phase 2,Phase 1

159351-69-6

70789204 6442177

Pomalidomide

Approved

Phase 1, Phase 2

19171-19-8

Suramin

Investigational

Phase 2

145-63-1

5361

Doxil

Approved June 1999

Phase 2,Phase 1

31703

Histamine Antagonists

Phase 2

Analgesics

Phase 2

Histamine H1 Antagonists

Phase 2

Immunoglobulins

Phase 2,Phase 1,Early Phase 1

Immunologic Factors

Phase 2,Phase 1,Early Phase 1

Antipyretics

Phase 2

Antibodies

Phase 2,Phase 1,Early Phase 1

Antibodies, Monoclonal

Phase 2,Phase 1,Early Phase 1

Pharmaceutical Solutions

Phase 2,Phase 1

Antiprotozoal Agents

Phase 2

Antiparasitic Agents

Phase 2

Anthelmintics

Phase 2

Hormone Antagonists

Phase 2,Phase 1

Antineoplastic Agents, Hormonal

Phase 2,Phase 1

Hormones

Phase 2,Phase 1

glucocorticoids

Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 2,Phase 1

Alkylating Agents

Phase 2,Phase 1

Antirheumatic Agents

Phase 2,Phase 1

Immunosuppressive Agents

Phase 2,Phase 1

Anti-Inflammatory Agents

Phase 2,Phase 1

Angiogenesis Modulating Agents

Phase 2,Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 2,Phase 1

Anti-Bacterial Agents

Phase 2,Phase 1

Antineoplastic Agents, Alkylating

Phase 2,Phase 1

Antimetabolites

Phase 2,Phase 1

Anti-Retroviral Agents

Phase 2,Early Phase 1

Anti-HIV Agents

Phase 2,Early Phase 1

Reverse Transcriptase Inhibitors

Phase 2

Nucleic Acid Synthesis Inhibitors

Phase 2,Phase 1

Interventional clinical trials:

(show all 31)

#	Name	Status	NCT ID	Phase	Drugs
1	Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease	Withdrawn	NCT00361933	Phase 4	Valganciclovir
2	A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease	Completed	NCT01024036	Phase 2	Siltuximab;Placebo;Best Supportive Care (BSC)
3	A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease	Completed	NCT01400503	Phase 2	Siltuximab
4	Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease	Completed	NCT00002652	Phase 2	suramin
5	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis	Completed	NCT00132015	Phase 2	tanespimycin
6	TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial	Recruiting	NCT03043105	Phase 2	Thalidomide, cyclophosphamide and prednisone
7	Tocilizumab for KSHV-Associated Multicentric Castleman Disease	Recruiting	NCT01441063	Phase 2	Zidovudine;Tocilizumab;Valganciclovir (VGC)
8	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	Recruiting	NCT00092222	Phase 2	Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
9	Siltuximab in Schizophrenia	Recruiting	NCT02796859	Phase 1, Phase 2	Siltuximab;normal saline
10	Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease	Not yet recruiting	NCT03933904	Phase 2	Sirolimus
11	Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy	Terminated	NCT00127569	Phase 2	Rituximab
12	Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas	Withdrawn	NCT02228512	Phase 1, Phase 2	Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
13	Dose-escalation Study of Oral CX-4945	Unknown status	NCT00891280	Phase 1	CX-4945 oral formulation
14	A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment	Completed	NCT01183598	Phase 1	tocilizumab [RoActemra/Actemra]
15	A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease	Completed	NCT00412321	Phase 1	CNTO 328
16	An Open-Label Trial of Tocilizumab in Schizophrenia	Completed	NCT01696929	Phase 1	Tocilizumab
17	Tocilizumab in Schizophrenia	Recruiting	NCT02874573	Phase 1	Tocilizumab;Normal saline
18	Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma	Recruiting	NCT02659930	Phase 1	liposomal doxorubicin;pomalidomide
19	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Recruiting	NCT01552434	Phase 1	Temsirolimus;Valproic Acid
20	Rituximab Hyaluronidase and Combination Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda	Not yet recruiting	NCT03864419	Phase 1	Cyclophosphamide;Vincristine;Methotrexate;Doxorubicin;Doxorubicin Hydrochloride;Prednisone;Etoposide
21	Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	Terminated	NCT02109224	Phase 1	Ibrutinib
22	Epithelioid Hemangioma of Bone And Soft Tissue	Completed	NCT03169595
23	Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials	Completed	NCT00695422
24	International Registry for Patients With Castleman Disease	Recruiting	NCT02817997
25	Unlock the Cell: Castleman's Disease Flow Cytometry Study	Recruiting	NCT02853968
26	Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease	Recruiting	NCT03300830
27	Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer	Recruiting	NCT00006518
28	Registry for Adults With Plasma Cell Disorders (PCD's)	Recruiting	NCT03717844
29	Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors	Terminated	NCT02080416	Early Phase 1	Nelfinavir
30	Castleman Disease Collaborative Network Biobank	Withdrawn	NCT02871050
31	Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis	Withdrawn	NCT02805868	Early Phase 1

Search NIH Clinical Center for Castleman Disease

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :

siltuximab

Cochrane evidence based reviews: castleman disease

Sources

Genetic Tests for Castleman Disease

Sources

Anatomical Context for Castleman Disease

MalaCards organs/tissues related to Castleman Disease:

⁴²

Lymph Node, B Cells, T Cells, Bone, Lung, Prostate, Liver

Sources

Publications for Castleman Disease

Articles related to Castleman Disease:

(show top 50) (show all 559)

#	Title	Authors	Year
1	Rheumatoid arthritis-like active synovitis with T-cell activation in a case of idiopathic multicentric Castleman disease: A case report. ( 31045763 )	Otsuka M...Kawakami A	2019
2	Amyloidosis secondary to intrapulmonary Castleman disease mimicking pulmonary hyalinizing granuloma-like clinical features: A rare case report. ( 30946344 )	Wang ST...Mao YY	2019
3	Hyaline vascular-type unicentric Castleman disease presenting as a subcutaneous nodule in a child. ( 30156317 )	Hanamura T...Akiyama M	2019
4	Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. ( 30203839 )	Morra DE...Fajgenbaum DC	2019
5	A prospective description of HIV-associated multicentric Castleman disease in Malawi. ( 30442726 )	Tomoka T...Gopal S	2019
6	Spontaneous middle lobe torsion in a patient with multicentric Castleman disease: A case report. ( 30467976 )	Gamble EL...Krishnan R	2019
7	Concomitant perinephric Castleman disease and renal cell carcinoma initially suspected to be metastasis: A case report and 24 months follow up. ( 30479965 )	Dong Y...Wang LH	2019
8	Radiologic and Histopathologic Features in an Intracranial Localized Castleman Disease: A Case Report and Review of Literature. ( 30586033 )	Escribano Paredes JB...Francisco JBC	2019
9	Recurrent PDGFRB mutations in unicentric Castleman disease. ( 30607019 )	Li Z...Zhang M	2019
10	Tuberculous lymphadenitis mimicking Castleman disease-like histological features. ( 30632056 )	Ide M...Ogino T	2019
11	Tufted angioma-like lesion associated with VEGF and IL-6 in TAFRO syndrome: Is it a common histological feature of multicentric Castleman disease/POEMS syndrome? ( 30632181 )	Fujita K...Hatta K	2019
12	An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. ( 30642741 )	Kurose N...Yamada S	2019
13	Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. ( 30680887 )	Sopfe J...Cost CR	2019
14	Castleman disease presenting with jaundice: A case report and review of literature. ( 30746379 )	Zhai B...Sun XY	2019
15	Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. ( 30760451 )	Zhang L...Li J	2019
16	A Case of Castleman Disease With Recurrence in the Neck: Case Report and Literature Review. ( 30825440 )	Feng F...Liu W	2019
17	Development of Castleman Disease in the Paravertebral Space Mimicking a Neurogenic Tumor. ( 30834220 )	Kwak YJ...Park IK	2019
18	Unusual case of human herpesvirus 8-positive large B-cell lymphoma associated with Castleman disease. ( 30899504 )	Sukswai N...Khoury JD	2019
19	Castleman Disease in a Patient with Common Variable Immunodeficiency. ( 30906603 )	Ricciardi L...Macr? A	2019
20	Successful treatment of a child with idiopathic multicentric Castleman disease associated with hemophagocytic lymphohistiocytosis using tocilizumab. ( 30989798 )	Wei A...Wang T	2019
21	Castleman Disease Presenting as a Supraclavicular Neck Mass in a Child. ( 30991840 )	Cohn JE...Terk AR	2019
22	Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases. ( 31016730 )	Boutboul D...Galicier L	2019
23	Castleman Disease Masquerading as the Posterior Mediastinal Mass on 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography. ( 31040538 )	Gupta V...Mahajan H	2019
24	Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report . ( 29701172 )	Yamada Y...Masaki T	2018
25	Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? ( 28401573 )	Abid MB...Lowry L	2018
26	Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan. ( 28880697 )	Fujimoto S...Yoshizaki K	2018
27	Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. ( 29124835 )	Zhang X...Cai Q	2018
28	Castleman disease: delineating the spectrum. ( 29143317 )	Alzahrani M...Leitch HA	2018
29	The full spectrum of Castleman disease: 273 patients studied over 20 years. ( 29143319 )	Oksenhendler E...Galicier L	2018
30	Epidemiology of Castleman Disease. ( 29157611 )	Simpson D	2018
31	Castleman Disease Pathogenesis. ( 29157613 )	Fajgenbaum DC...Shilling D	2018
32	The Peripheral Neuropathies of POEMS Syndrome and Castleman Disease. ( 29157616 )	Mauermann ML	2018
33	The Role of Interleukin-6 in Castleman Disease. ( 29157617 )	Yoshizaki K...Koga T	2018
34	Pathology of Castleman Disease. ( 29157618 )	Wu D...Jaffe ES	2018
35	Diagnosis of Castleman Disease. ( 29157619 )	Szalat R...Munshi NC	2018
36	Unicentric Castleman Disease. ( 29157620 )	Wong RSM	2018
37	Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )	Lurain K...Uldrick TS	2018
38	Treatment of Idiopathic Castleman Disease. ( 29157622 )	van Rhee F...Stone K	2018
39	Castleman Disease. ( 29157623 )	van Rhee F...Munshi NC	2018
40	EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity. ( 29198143 )	Shivane A...Smith MEF	2018
41	Castleman Disease and Rosai-Dorfman Disease. ( 29217303 )	Piris MA...Celeiro-Mu?oz C	2018
42	Plasma Cell Variant Multicentric Castleman Disease and Kaposi's Sarcoma in a Treatment-Naive HIV-Infected Patient. ( 29345958 )	Patel AS...Goswami ND	2018
43	Successful use of rituximab in glomerular basement membrane nephritis associated with HIV interstitial nephritis secondary to Castleman disease . ( 29424337 )	Calabro N...Kerns E	2018
44	Tocilizumab Cannot Prevent the Development of Bronchiolitis Obliterans in Patients With Castleman Disease-Associated Paraneoplastic Pemphigus. ( 29389687 )	Gu L...Ye S	2018
45	Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus. ( 30128272 )	Raza HA...Cartin-Ceba R	2018
46	Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease. ( 29486963 )	Quesada AE...Thakral B	2018
47	Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. ( 29496669 )	Nagy A...Ohgami RS	2018
48	The Clinical and Immunologic Features of Patients With Combined Anti-GBM Disease and Castleman Disease. ( 29510921 )	Gu QH...Zhao MH	2018
49	Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease. ( 29557805 )	Tahir M...Charles L	2018
50	Castleman disease in the hilum liver mimicking the lymph node metastasis of hepatocellular carcinoma on 18F-FDG PET/CT: A case report. ( 29561464 )	Hu Y...Shi H	2018

Sources

Genes for Castleman Disease

Genes related to Castleman Disease (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	IL6	Interleukin 6	Protein Coding	35.26	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18784373 9462253 17075601 (more) 19270642 10340005 10979949 12633573 8043430 9403701 8061104 8695726 7883866 10830746 2384605 9477139 2366383 2049864 1285994 1643291 19447768 7971857 7744000 8143505 8371004 19857312 17325481 17028666 15223659 12731671 9546694 17766835 15182131 11781250 10207568 1571900 17483056 17527041 17550864 17214583 15992152 10512402 9280606 9144766 8492420 20110057 20182422 19483409 19139722 19730402 17075187 16922487 16129906 14677035 12015752 10874763 15745091 12521189 11053081 20439324 20410258 18974624 15871519 15251133 11895764 10607684 15989626 9132332 8499003 1493429 1632458 1987276 10861641 10848977 10762119 10741750 9864581 9613678 8990099 7494511 7910717 19010373 8890706 8375854 20403026 10654928 10515899
2	IL6R	Interleukin 6 Receptor	Protein Coding	30.31	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	8890706 12633573
3	KRT15	Keratin 15	Protein Coding	28.52	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	11752170
4	CR2	Complement C3d Receptor 2	Protein Coding	23.56	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	CRP	C-Reactive Protein	Protein Coding	23.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	CR1	Complement C3b/C4b Receptor 1 (Knops Blood Group)	Protein Coding	23.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	EVPL	Envoplakin	Protein Coding	22.06	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	PPL	Periplakin	Protein Coding	21.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	21.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	BCL6	BCL6 Transcription Repressor	Protein Coding	21.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	DSP	Desmoplakin	Protein Coding	21.5	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	PAX5	Paired Box 5	Protein Coding	20.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	IL10	Interleukin 10	Protein Coding	20.42	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	IL9	Interleukin 9	Protein Coding	19.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	DSG1	Desmoglein 1	Protein Coding	19.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Castleman Disease

Sources

Expression for Castleman Disease

Search GEO for disease gene expression data for Castleman Disease.

Sources

Pathways for Castleman Disease

Pathways related to Castleman Disease according to KEGG:

³⁸

#	Name	Kegg Source Accession
1	Cytokine-cytokine receptor interaction	hsa04060
2	JAK-STAT signaling pathway	hsa04630
3	Hematopoietic cell lineage	hsa04640

Pathways related to Castleman Disease according to GeneCards Suite gene sharing:

(show all 19)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁷ Show member pathways Immune System ⁶⁷ Neutrophil degranulation ⁶⁷	13.66	BCL6 CR1 CRP DSG1 DSP IL10
2	Cytokine Signaling in Immune system ⁶⁷ Show member pathways Signaling by Interleukins ⁶⁷	13.13	BCL6 IL10 IL6 IL6R IL9 VEGFA
3	JAK-STAT signaling pathway (KEGG) ⁶⁶ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁷ JAK-STAT signaling pathway ³⁸	12.14	IL10 IL6 IL6R IL9
4	Keratinization ⁶⁷ Show member pathways Formation of the cornified envelope ⁶⁷	12.11	DSG1 DSP EVPL KRT15 PPL
5	FoxO signaling pathway ³⁸ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	11.9	BCL6 IL10 IL6
6	Immune response Lectin induced complement pathway ²³ Show member pathways Activation of C3 and C5 ⁶⁷ Immune response Alternative complement pathway ²³ Immune response Classical complement pathway ²³ Regulation of Complement cascade ⁶⁷	11.88	CR1 CR2 CRP
7	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	11.88	IL10 IL6 IL6R VEGFA
8	Th1 Differentiation Pathway ⁶⁶ Show member pathways IL27-mediated signaling events ¹ Th17 Differentiation Pathway ⁶⁶	11.85	IL10 IL6 IL6R
9	Immune response IFN gamma signaling pathway ²³ Show member pathways IFN-gamma pathway ¹	11.84	IL10 IL6 IL6R IL9
10	Cytoskeleton remodeling Neurofilaments ²³ Show member pathways Cytoskeleton remodeling Keratin filaments ²³	11.72	DSP EVPL PPL
11	HIF-1 signaling pathway ³⁸	11.67	IL6 IL6R VEGFA
12	Jak-Stat Signaling Pathway (sino) ⁶⁸	11.66	IL10 IL6 IL6R
13	Hematopoietic cell lineage ³⁸	11.44	CR1 CR2 IL6 IL6R
14	Interleukin-4 and 13 signaling ⁶⁷	11.41	BCL6 IL10 IL6 IL6R VEGFA
15	Hepatitis C and Hepatocellular Carcinoma ¹	11.34	IL6 IL6R VEGFA
16	Malaria ³⁸	11.3	CR1 IL10 IL6
17	Differentiation Pathway ¹	11.26	IL6 IL6R VEGFA
18	Overview of nanoparticle effects ¹	10.85	CRP IL6
19	B Cell Development Pathways ⁶⁶	10.75	BCL6 CR2 IL10 IL6R PAX5

Sources

GO Terms for Castleman Disease

Cellular components related to Castleman Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	intermediate filament	GO:0005882	9.56	DSP EVPL KRT15 PPL
2	ficolin-1-rich granule membrane	GO:0101003	9.5	CR1 DSG1 DSP
3	cornified envelope	GO:0001533	9.26	DSG1 DSP EVPL PPL
4	interleukin-6 receptor complex	GO:0005896	9.16	IL6 IL6R
5	desmosome	GO:0030057	8.92	DSG1 DSP EVPL PPL

Biological processes related to Castleman Disease according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of signaling receptor activity	GO:0010469	9.85	IL10 IL6 IL6R IL9 VEGFA
2	inflammatory response	GO:0006954	9.8	BCL6 CRP IL10 IL6 IL9
3	epidermis development	GO:0008544	9.75	DSP EVPL KRT15
4	wound healing	GO:0042060	9.73	DSP EVPL PPL
5	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	9.71	IL6 IL6R VEGFA
6	B cell differentiation	GO:0030183	9.67	BCL6 CR2 IL10
7	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.65	IL6 IL6R VEGFA
8	cytokine-mediated signaling pathway	GO:0019221	9.65	BCL6 IL10 IL6 IL6R VEGFA
9	positive regulation of chemokine production	GO:0032722	9.59	IL6 IL6R
10	interleukin-6-mediated signaling pathway	GO:0070102	9.58	IL6 IL6R
11	complement receptor mediated signaling pathway	GO:0002430	9.57	CR1 CR2
12	positive regulation of leukocyte chemotaxis	GO:0002690	9.55	IL6 IL6R
13	acute-phase response	GO:0006953	9.54	CRP IL6 IL6R
14	positive regulation of cellular component movement	GO:0051272	9.52	BCL6 VEGFA
15	negative regulation of lipid storage	GO:0010888	9.51	CRP IL6
16	type 2 immune response	GO:0042092	9.43	BCL6 IL10
17	keratinization	GO:0031424	9.35	DSG1 DSP EVPL KRT15 PPL
18	intermediate filament cytoskeleton organization	GO:0045104	9.33	DSP EVPL PPL
19	hepatic immune response	GO:0002384	9.32	IL6 IL6R
20	cornification	GO:0070268	9.02	DSG1 DSP EVPL KRT15 PPL

Molecular functions related to Castleman Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	structural constituent of cytoskeleton	GO:0005200	9.43	DSP KRT15 PPL
2	cytokine activity	GO:0005125	9.26	IL10 IL6 IL9 VEGFA
3	interleukin-6 receptor binding	GO:0005138	9.16	IL6 IL6R
4	growth factor activity	GO:0008083	9.02	IL10 IL6 IL6R IL9 VEGFA

Sources

Sources for Castleman Disease

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia

Castleman Disease

Aliases & Classifications for Castleman Disease

MalaCards integrated aliases for Castleman Disease:

Classifications:

External Ids:

Summaries for Castleman Disease

Related Diseases for Castleman Disease

Diseases related to Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Castleman Disease:

Symptoms & Phenotypes for Castleman Disease

MGI Mouse Phenotypes related to Castleman Disease:

Drugs & Therapeutics for Castleman Disease

Drugs for Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 74 / NDF-RT 52 :

Cochrane evidence based reviews: castleman disease

Genetic Tests for Castleman Disease

Anatomical Context for Castleman Disease

MalaCards organs/tissues related to Castleman Disease:

Publications for Castleman Disease

Articles related to Castleman Disease:

Genes for Castleman Disease

Genes related to Castleman Disease (0 elite genes):

Variations for Castleman Disease

Expression for Castleman Disease

Pathways for Castleman Disease

Pathways related to Castleman Disease according to KEGG:

Pathways related to Castleman Disease according to GeneCards Suite gene sharing:

GO Terms for Castleman Disease

Cellular components related to Castleman Disease according to GeneCards Suite gene sharing:

Biological processes related to Castleman Disease according to GeneCards Suite gene sharing:

Molecular functions related to Castleman Disease according to GeneCards Suite gene sharing:

Sources for Castleman Disease

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :